Eli Lilly and Co. (LLY) Tuesday said it will lower the list price of Insulin Lispro Injection in the U.S. by an additional 40 percent effective January 1, 2022. The move will effectively bring the list price down to 2008 levels, the company said.
The drug maker said the new list price will apply to all its non-branded insulins, including Insulin Lispro Injection, a lower list-priced alternative to Humalog U-100.
The new list price for Insulin Lispro Injection will be $82.41 for individual vials and $159.12 for a pack of five pens. This is 70 percent less than Lilly's branded Humalog U-100 counterparts. Lilly's Insulin Lispro Injection, 100 units/mL was first introduced at half the list price of branded Humalog (insulin lispro injection, 100 units/mL) in 2019.
Insulin Lispro Injection can be ordered through all U.S. retail pharmacies.
According to the company, the new lower list price is the latest among numerous options that can reduce out-of-pocket costs for Lilly insulin at U.S. retail pharmacies.
People using any Lilly insulin, including Insulin Lispro Injection, can fill their monthly prescription for $35 through the Lilly Insulin Value Program for people with commercial insurance or who are uninsured, and the Senior Savings Model for seniors in participating Medicare Part D plans.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.